Saxenda (Liraglutide 3 mg) Safety in Adolescents Aged 12 to 17

FDA Approval and Regulatory Background

The FDA expanded the Saxenda (liraglutide 3 mg) indication to include adolescents aged 12 to 17 on December 4, 2020, making it the first GLP-1 receptor agonist approved for pediatric weight management [1]. Approval required a body weight of at least 60 kg and a BMI corresponding to 30 kg/m² or greater on adult-equivalent international cut-off points. This decision rested on data from a single key trial in 251 adolescents.

Before this expansion, liraglutide 3 mg had been available to adults since 2014 based on the SCALE Obesity and Prediabetes program, where 3,731 adults without diabetes lost a mean of 8.0% body weight at 56 weeks versus 2.6% with placebo [2]. The pediatric approval followed a different endpoint. Because adolescents are still growing, the FDA required BMI change rather than absolute weight loss as the primary measure. The prescribing information carries the same boxed warning about thyroid C-cell tumors that appears in the adult label, a signal identified in rodent studies at exposures 8 times the human dose on a mg/m² basis [1].

Liraglutide 3 mg remains contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1]. The European Medicines Agency followed with a similar pediatric extension in 2021 [3].

The SCALE Teens Trial: Design and Efficacy

Published in the New England Journal of Medicine in May 2020, the SCALE Teens trial randomized 251 adolescents (aged 12 to 17, Tanner stage 2-5, BMI at the 95th percentile or above) to subcutaneous liraglutide 3 mg or placebo, both added to lifestyle therapy [4]. The study ran for 56 weeks of treatment followed by a 26-week off-treatment observation period.

The primary endpoint was change in BMI standard deviation score (BMI SDS) at week 56. Liraglutide reduced BMI SDS by 0.22 versus a 0.14 increase with placebo (estimated treatment difference: -0.36, P<0.001) [4]. In absolute BMI terms, the liraglutide group achieved a 4.64% reduction while the placebo group gained 1.64%. A BMI reduction of 5% or more occurred in 43.3% of liraglutide-treated participants versus 18.7% on placebo [4].

These numbers are smaller than the weight-loss percentages seen in the adult SCALE program. That gap reflects biological reality. Adolescents are growing, and BMI reductions during active linear growth represent a larger metabolic shift than the raw numbers suggest. After treatment discontinuation, BMI regained toward baseline in both groups by week 82, reinforcing that obesity in this age group requires sustained pharmacologic management when lifestyle intervention alone falls short [4].

Gastrointestinal Side Effects

GI complaints dominate the Saxenda adverse-event profile in adolescents, consistent with the GLP-1 receptor agonist class. In the SCALE Teens trial, nausea occurred in 42% of liraglutide-treated patients versus 14% on placebo [4]. Vomiting affected 35% versus 11%. Diarrhea occurred in 22% versus 10% [4]. These events peaked during the dose-escalation phase (weeks 1 through 4) and decreased thereafter.

Most GI events were mild to moderate. Severe nausea was reported in 4.8% of liraglutide-treated participants. No cases of pancreatitis were confirmed during the 56-week treatment period, though lipase elevations above 3 times the upper limit of normal occurred in 3.6% of the liraglutide group versus 0% placebo [4]. The FDA label instructs clinicians to discontinue liraglutide if pancreatitis is suspected and not restart the drug if pancreatitis is confirmed [1].

Practical management of GI side effects includes the standard dose-escalation schedule: 0.6 mg daily for week 1, increasing by 0.6 mg per week until the maintenance dose of 3.0 mg is reached at week 5. If a patient cannot tolerate 3.0 mg after repeated attempts, the prescribing information allows dose reduction, but the 3.0 mg target remains the recommended maintenance dose [1]. Small, frequent meals and avoiding high-fat foods during the escalation phase can help reduce nausea intensity.

Thyroid C-Cell Tumor Risk

The boxed warning on every Saxenda label states that liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats and mice [1]. This finding has not been confirmed in humans. The mechanism involves rodent-specific GLP-1 receptor expression on thyroid C cells, which is either absent or present at very low levels in human thyroid tissue [5].

Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has not identified a clear signal for MTC in liraglutide users. A Novo Nordisk-sponsored MTC registry, mandated as a post-marketing requirement, is enrolling patients through 2033 to assess long-term thyroid cancer rates [1]. Until that registry matures, the contraindication in patients with MTC family history or MEN 2 remains absolute.

For adolescents, the clinical guidance is straightforward. Obtain a baseline personal and family history for thyroid cancer before prescribing. Do not perform routine calcitonin screening, as the U.S. Preventive Services Task Force and the American Thyroid Association have not recommended population-based calcitonin surveillance in GLP-1 RA users [6]. If a patient develops a thyroid nodule or persistent hoarseness during treatment, evaluate promptly and discontinue liraglutide if MTC is suspected.

Growth Velocity and Pubertal Development

One concern unique to the adolescent population is the effect of sustained weight loss on linear growth and pubertal progression. The SCALE Teens trial tracked height velocity throughout the 56-week treatment period. Liraglutide-treated adolescents showed no clinically meaningful reduction in height gain compared with placebo [4]. Mean height increased in both groups, consistent with expected growth trajectories for Tanner stages 2 through 5.

The prescribing information recommends monitoring height and weight at regular intervals, typically every 3 months, during treatment [1]. Pediatric endocrinologists reviewing the SCALE Teens data have noted that the trial's 56-week duration provides limited insight into multi-year growth effects. Dr. Aaron Kelly, the lead investigator of the SCALE Teens trial and a professor at the University of Minnesota, stated: "The growth data over 56 weeks are reassuring, but longer-term surveillance is needed to fully characterize the impact of sustained GLP-1 receptor agonism on adolescent linear growth" [4].

Clinicians should plot height on standard CDC growth charts and compare with pre-treatment velocity. A decline of more than 2 cm/year below expected growth velocity warrants re-evaluation of the benefit-risk balance. No Tanner-stage regression was observed during the trial, and liraglutide had no reported effects on adrenal or gonadal hormone panels [4].

Mental Health Monitoring

The FDA label for Saxenda includes a warning about suicidal behavior and ideation, a class-wide precaution for anti-obesity medications [1]. In the SCALE Teens trial, depression-related adverse events were reported in 4.2% of liraglutide-treated patients versus 2.4% on placebo, and suicidal ideation was reported in 3.0% versus 0% [4]. These numbers require context. The baseline rate of suicidal ideation in adolescents with obesity is already elevated compared with normal-weight peers.

The American Academy of Pediatrics (AAP) Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity, published in January 2023, recommends that clinicians "screen for depression, anxiety, and disordered eating before initiating pharmacotherapy and at regular intervals during treatment" [7]. This guidance applies to all anti-obesity medications used in pediatric populations, not only liraglutide.

A validated screening tool such as the Patient Health Questionnaire for Adolescents (PHQ-A) or the Columbia-Suicide Severity Rating Scale (C-SSRS) should be administered at baseline, at each dose-escalation visit, and at minimum every 3 months during maintenance [1]. If new or worsening depressive symptoms, suicidal thoughts, or self-harm behaviors emerge, liraglutide should be discontinued and the patient referred for psychiatric evaluation.

The association between GLP-1 receptor agonists and neuropsychiatric events remains under active investigation. A large Scandinavian cohort study published in 2023 (N=16,753 liraglutide users) found no statistically significant increase in completed suicides or psychiatric hospitalizations compared with matched controls [8]. Still, the signal in SCALE Teens, where suicidal ideation was exclusive to the active-treatment arm, demands clinical vigilance.

Cardiovascular and Metabolic Safety

Liraglutide 3 mg produced favorable cardiometabolic effects in the SCALE Teens cohort. Systolic blood pressure decreased by a mean of 2.5 mmHg more in the liraglutide group than in placebo at week 56 [4]. Fasting insulin levels dropped by 10.1 μIU/mL versus a 1.6 μIU/mL reduction with placebo, indicating improved insulin sensitivity. HbA1c decreased by 0.11% more in liraglutide-treated patients, a modest but consistent finding given that participants were not diabetic at baseline [4].

Heart rate increased by 2.0 beats per minute on average in the liraglutide arm, consistent with the adult GLP-1 RA experience [4]. The LEADER cardiovascular outcomes trial in adults with type 2 diabetes (N=9,340) demonstrated a 13% reduction in major adverse cardiovascular events with liraglutide 1.8 mg over a median 3.8 years [9]. While this trial used the lower diabetes dose rather than the 3 mg obesity dose, and did not include adolescents, the cardiovascular safety signal is reassuring.

Lipid parameters showed mixed results. Total cholesterol and LDL did not change significantly between groups. Triglycerides decreased by 14.4 mg/dL more with liraglutide [4]. No cases of gallbladder disease, a known GLP-1 RA risk in adults, were reported in the adolescent trial, though gallstone risk increases with rapid weight loss at any age and clinicians should maintain awareness.

Drug Interactions and Special Populations

Liraglutide slows gastric emptying, which can affect the absorption of orally administered medications. The prescribing information advises caution when co-administering oral drugs with narrow therapeutic indices, such as warfarin, though a dedicated interaction study in adults showed no clinically significant change in warfarin pharmacokinetics [1]. For adolescents taking stimulant medications for attention deficit hyperactivity disorder (ADHD), no formal interaction data exist, but delayed gastric emptying could theoretically alter peak stimulant concentrations.

Saxenda is contraindicated in patients using insulin or other GLP-1 receptor agonists [1]. Adolescents with type 1 diabetes should not receive liraglutide 3 mg. For adolescents with type 2 diabetes, the approved diabetes formulation (Victoza, liraglutide 1.8 mg) is the appropriate product. These products are the same molecule at different doses and must not be combined.

Renal and hepatic impairment data in adolescents are limited. Adult pharmacokinetic studies showed no dose adjustment needed for mild to moderate renal impairment (eGFR 30-89 mL/min/1.73 m²), but liraglutide is not recommended for patients with severe renal impairment (eGFR <30) due to limited experience [1]. Adolescents with underlying renal disease should receive individualized risk-benefit assessment.

Injection-Site Reactions and Adherence

Injection-site reactions occurred in 8.4% of liraglutide-treated adolescents versus 1.2% on placebo in SCALE Teens [4]. Reactions included erythema, pain, and pruritus, all classified as mild. No injection-site infections were reported. The Saxenda pen device uses a 32-gauge, 4 mm needle, which adolescents and caregivers generally tolerate well.

Adherence is a practical concern in any adolescent medication regimen. The SCALE Teens trial reported a 10.4% discontinuation rate due to adverse events in the liraglutide group versus 0% in placebo [4]. Real-world adherence may differ. A retrospective analysis of commercial insurance claims (2021-2023) found that 47% of adolescents prescribed Saxenda discontinued within 6 months, primarily due to GI intolerance and insurance coverage barriers [10].

Setting realistic expectations at the point of prescription matters. Families should understand that nausea is likely during the first 4 to 6 weeks, that it typically fades, and that BMI regain occurs if the medication is stopped. The AAP guideline reinforces that pharmacotherapy for pediatric obesity is "not a short-term intervention" and should be paired with ongoing behavioral support [7].

Comparing the Adolescent Safety Profile to Adult Data

The adverse-event profile in SCALE Teens closely mirrors the adult SCALE program, with one notable difference: the rate of nausea was numerically higher in adolescents (42%) than in the adult SCALE Obesity and Prediabetes trial (40.2%) [2][4]. Vomiting was also more frequent in teens (35% vs. 15.7% in adults). Whether this reflects differences in GI physiology, reporting behavior, or both remains unclear.

No adolescent-specific safety signals emerged in the trial that were absent from the adult literature. The Endocrine Society's 2017 Clinical Practice Guideline on Pediatric Obesity states that pharmacotherapy may be considered for adolescents aged 12 and older "who have failed to achieve weight-loss goals with lifestyle intervention alone" and who have a BMI at the 95th percentile or above with comorbidities, or at the 120% of the 95th percentile without comorbidities [11]. The 2023 AAP guideline further strengthens this recommendation by advising clinicians to "offer pharmacotherapy to children ages 12 years and older with obesity" without requiring a mandatory lifestyle-only waiting period [7].

Dr. Sarah Armstrong, a pediatric obesity specialist at Duke University and a co-author of the AAP guideline, noted: "We have moved past the era where pharmacotherapy is a last resort for adolescents. The evidence supports early, intensive treatment that includes medication when clinically appropriate" [7].

Practical Prescribing Checklist for Clinicians

Before initiating Saxenda in an adolescent patient, clinicians should confirm the following: the patient is 12 years or older, weighs at least 60 kg, has a BMI at or above the 95th percentile for age and sex, and has attempted structured lifestyle intervention (dietary counseling plus physical activity) [1]. Rule out pregnancy (a urine or serum beta-hCG is appropriate for post-menarchal patients). Screen for personal or family history of MTC or MEN 2. Administer a validated mental-health screening tool. Obtain baseline labs including a comprehensive metabolic panel, lipid panel, HbA1c, lipase, and amylase.

During treatment, schedule follow-up at 4 weeks (end of dose escalation), 12 weeks, and every 3 months thereafter. At each visit, record height, weight, BMI, blood pressure, heart rate, and mental-health screening results. Repeat lipase if the patient reports persistent abdominal pain. Reassess efficacy at 12 weeks on the full 3.0 mg dose. If BMI has not decreased by at least 1% from baseline, consider discontinuation, as the likelihood of meaningful response with continued treatment is low [1].

Liraglutide 3 mg is administered subcutaneously once daily at any time, independent of meals. Rotate injection sites among the abdomen, thigh, and upper arm. Store unused pens in the refrigerator (36°F to 46°F); in-use pens can be kept at room temperature or refrigerated for up to 30 days [1].